These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 15930279

  • 1. Tachyplesin activates the classic complement pathway to kill tumor cells.
    Chen J, Xu XM, Underhill CB, Yang S, Wang L, Chen Y, Hong S, Creswell K, Zhang L.
    Cancer Res; 2005 Jun 01; 65(11):4614-22. PubMed ID: 15930279
    [Abstract] [Full Text] [Related]

  • 2. Mechanism of tachyplesin I injury to bacterial membranes and intracellular enzymes, determined by laser confocal scanning microscopy and flow cytometry.
    Hong J, Guan W, Jin G, Zhao H, Jiang X, Dai J.
    Microbiol Res; 2015 Jan 01; 170():69-77. PubMed ID: 25267486
    [Abstract] [Full Text] [Related]

  • 3. RGD-Tachyplesin inhibits tumor growth.
    Chen Y, Xu X, Hong S, Chen J, Liu N, Underhill CB, Creswell K, Zhang L.
    Cancer Res; 2001 Mar 15; 61(6):2434-8. PubMed ID: 11289111
    [Abstract] [Full Text] [Related]

  • 4. Effects of tachyplesin and n-sodium butyrate on proliferation and gene expression of human gastric adenocarcinoma cell line BGC-823.
    Shi SL, Wang YY, Liang Y, Li QF.
    World J Gastroenterol; 2006 Mar 21; 12(11):1694-8. PubMed ID: 16586536
    [Abstract] [Full Text] [Related]

  • 5. Characterization of Tachyplesin Peptides and Their Cyclized Analogues to Improve Antimicrobial and Anticancer Properties.
    Vernen F, Harvey PJ, Dias SA, Veiga AS, Huang YH, Craik DJ, Lawrence N, Troeira Henriques S.
    Int J Mol Sci; 2019 Aug 26; 20(17):. PubMed ID: 31455019
    [Abstract] [Full Text] [Related]

  • 6. Identification of C1q as a Binding Protein for Advanced Glycation End Products.
    Chikazawa M, Shibata T, Hatasa Y, Hirose S, Otaki N, Nakashima F, Ito M, Machida S, Maruyama S, Uchida K.
    Biochemistry; 2016 Jan 26; 55(3):435-46. PubMed ID: 26731343
    [Abstract] [Full Text] [Related]

  • 7. Effects of tachyplesin I on human U251 glioma stem cells.
    Ding H, Jin G, Zhang L, Dai J, Dang J, Han Y.
    Mol Med Rep; 2015 Apr 26; 11(4):2953-8. PubMed ID: 25434611
    [Abstract] [Full Text] [Related]

  • 8. High molecular weight non-immunoglobulin salivary agglutinins (NIA) bind C1Q globular heads and have the potential to activate the first complement component.
    Boackle RJ, Connor MH, Vesely J.
    Mol Immunol; 1993 Feb 26; 30(3):309-19. PubMed ID: 8433709
    [Abstract] [Full Text] [Related]

  • 9. Deletion of all cysteines in tachyplesin I abolishes hemolytic activity and retains antimicrobial activity and lipopolysaccharide selective binding.
    Ramamoorthy A, Thennarasu S, Tan A, Gottipati K, Sreekumar S, Heyl DL, An FY, Shelburne CE.
    Biochemistry; 2006 May 23; 45(20):6529-40. PubMed ID: 16700563
    [Abstract] [Full Text] [Related]

  • 10. In Vitro Study of Antitumor Effect of Antimicrobial Peptide Tachyplesin I in Combination with Cisplatin.
    Kuzmin DV, Emel'yanova AA, Kalashnikova MB, Panteleev PV, Ovchinnikova TV.
    Bull Exp Biol Med; 2018 Jun 23; 165(2):220-224. PubMed ID: 29922995
    [Abstract] [Full Text] [Related]

  • 11. Modified horseshoe crab peptides target and kill bacteria inside host cells.
    Amiss AS, von Pein JB, Webb JR, Condon ND, Harvey PJ, Phan MD, Schembri MA, Currie BJ, Sweet MJ, Craik DJ, Kapetanovic R, Henriques ST, Lawrence N.
    Cell Mol Life Sci; 2021 Dec 31; 79(1):38. PubMed ID: 34971427
    [Abstract] [Full Text] [Related]

  • 12. Quantitative Proteomic Profiling of Tachyplesin I Targets in U251 Gliomaspheres.
    Li X, Dai J, Tang Y, Li L, Jin G.
    Mar Drugs; 2017 Jan 18; 15(1):. PubMed ID: 28106765
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma.
    Skliris A, Happonen KE, Terpos E, Labropoulou V, Børset M, Heinegård D, Blom AM, Theocharis AD.
    Eur J Immunol; 2011 Feb 18; 41(2):437-49. PubMed ID: 21268013
    [Abstract] [Full Text] [Related]

  • 15. Specific inhibition of the classical complement pathway by C1q-binding peptides.
    Roos A, Nauta AJ, Broers D, Faber-Krol MC, Trouw LA, Drijfhout JW, Daha MR.
    J Immunol; 2001 Dec 15; 167(12):7052-9. PubMed ID: 11739526
    [Abstract] [Full Text] [Related]

  • 16. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW, Kadlec JV, Petrella EC, Bredehorst R, Vogel CW.
    Cancer Res; 1993 Feb 01; 53(3):592-9. PubMed ID: 8425193
    [Abstract] [Full Text] [Related]

  • 17. Covalent binding of C3b to C4b within the classical complement pathway C5 convertase. Determination of amino acid residues involved in ester linkage formation.
    Kim YU, Carroll MC, Isenman DE, Nonaka M, Pramoonjago P, Takeda J, Inoue K, Kinoshita T.
    J Biol Chem; 1992 Feb 25; 267(6):4171-6. PubMed ID: 1740458
    [Abstract] [Full Text] [Related]

  • 18. Action mechanism of tachyplesin I and effects of PEGylation.
    Imura Y, Nishida M, Ogawa Y, Takakura Y, Matsuzaki K.
    Biochim Biophys Acta; 2007 May 25; 1768(5):1160-9. PubMed ID: 17320042
    [Abstract] [Full Text] [Related]

  • 19. Complement-Mediated Neutralization of a Potent Neurotropic Human Pathogen, Chandipura Virus, Is Dependent on C1q.
    Kunnakkadan U, Nag J, Kumar NA, Mukesh RK, Suma SM, Johnson JB.
    J Virol; 2019 Oct 01; 93(19):. PubMed ID: 31315998
    [Abstract] [Full Text] [Related]

  • 20. Localization of the covalent C3b-binding site on C4b within the complement classical pathway C5 convertase, C4b2a3b.
    Kozono H, Kinoshita T, Kim YU, Takata-Kozono Y, Tsunasawa S, Sakiyama F, Takeda J, Hong K, Inoue K.
    J Biol Chem; 1990 Aug 25; 265(24):14444-9. PubMed ID: 2387864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.